Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-05-03
2005-05-03
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
06887882
ABSTRACT:
The present invention relation to a pharmaceutical composition comprising chelidonine or derivatives thereof, with pharmaceutically acceptable carriers. The compositions according to the present invention can selectively block hKv1.5 channels expressed preferentially in human atrial myocytes, and thus are useful as K+channel blockers and antiarrhythmic drugs.
REFERENCES:
patent: 4737503 (1988-04-01), Sakamoto et al.
patent: 4769452 (1988-09-01), Boulware
Beeton et al. Proceedings of the National Academy of the Sciences of the U.S.A., (Nov. 20, 2001) 98 (24) 13942-7 (ABSTRACT).*
Szewczyk et al. Biochemical pharmacology, (Sep. 1, 2000) 60 (5) 607-14 (ABSTRACT).*
Grahammer et al. Gastroenterology, (May 2001) 120 (6) 1363-71 (ABSTRACT).*
Sanguinetti and Keating “Role of Delayed Rectifier Potassium Channels in Cardiac . . . ”News Physiol. Sci. 12, 152-157 (1997).
Tristani-Firouzi et al. “Molecular Biology of K+Channels and Their Role . . . ”Physiology In Medicine 110, 50-59 (2001).
Fedida et al. “The 1997 Stevenson Award Lecture. Cardiac K+channel gating: cloned delayed rectifier . . . ”Can. J. Physiol. Pharmacol. 76, 77-89 (1998).
Grissmer “Potassium channels still hot” TIPS—Oct. 1997 (vol. 18), pp. 347-350.
Wang et al. “Effects of Flecainide, Quinidine, and 4-Aminopyridine on Transient Outward . . . ”J. Pharm. Exp. Thera. 272, 184-196 (1994).
Kwak et al. “Phosphorylation Is Required for Alteration of Kvl.5 K+Channel Function by the Kvβ1.3 Subunit”J. Biol. Chem. 274, 25355-25361 (1999).
Yang et al. “Inhibition of Cardiac Potassium Currents by the Vesnarinone Analog OPC-18790: Comparison . . . ”J. Pharm. Exper. Ther. 280, 1170-1175 (1996).
Roden “Mechanism and Management of Proarrhythmia”Am. J. Cardiol. 82, 491-571 (1998).
Katz “Selectivity and Toxicity of Antiarrhythmic Drugs: Molecular Interactions . . . ”Am. J. Med. 104, 179-195 (1998).
Deal et al. “Molecular Physiology of Cardiac Potassium Channels”Phys. Reviews76, 49-67 (1996).
Roden and Tamkun “Toward a Molecular View of Cardiac Arrhythmogenesis . . . ”TCM 4, 278-285 (1994).
Kwak et al. “KR-30450, a Newly Synthesized Benzopyran Derivative, Activates . . . ”J. Pharm. Exp. Thera. 275,807-812 (1995).
Hanaoka et al. “A Novel and Biomimetic Synthesis of (±)-Chelamine . . . ”Chem. Let. 739-742 (1986).
Snatzke et al. “Absolute Configuration and Chiroptical Properties of Chelidonine . . . ”Tetrahedron 26, 5013-5028 (1970).
Panzer et al. “Ukraine™, a semisyntheticChelidonium majusalkaloid derivative, acts by . . . ”Cancer Letters 160149-157 (2000).
Grynkiewicz et al. “Synthesis and biological activity of O-acyl and O-alkyl chelidonine derivatives”Eur. J. Med. Chem. 36, 951-960 (2001).
Panzer et al. “The effects of chelidonoine on tubulin polymerization, cell cycle progression and . . . ”Eur. J. Cell Biol. 80, 111-118 (2001).
Hiller et al. “Antispasmodic and Relaxant Activity of Chelidonine, Protopine, Coptisine . . . ”Planta Medica 64, 758-760 (1998).
Chae Soo-Wan
Eun Jae-Soon
Kim Dae-Keun
Kwak Yong-Geun
Chae Soo-Wan
Eun Jae-Soon
Henley III Raymond J.
Heslin Rothenberg Farley & & Mesiti P.C.
Jung Young-Hoon
LandOfFree
Pharmaceutical compositions comprising chelidonine or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions comprising chelidonine or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions comprising chelidonine or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3372692